HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $195

HC Wainwright & Co. analyst Swayampakula Ramakanth has reaffirmed a Buy rating on Mirum Pharmaceuticals (NASDAQ: MIRM) and increased the price target from $140 to $195. This adjustment reflects a positive outlook on the company's performance.